Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于召开2025年年度暨2026年第一季度业绩说明会的公告
Regulatory Filings Classification · 46% confidence The document is an announcement by Tasly Pharmaceutical (600535) scheduling a 2025 Annual and Q1 2026 performance briefing (业绩说明会), providing timing, location, participation instructions, and company contacts. It is not the full financial report, not an earnings release of results, nor the transcript or slides—it simply notifies investors of an upcoming earnings explanation meeting. This type of notice does not correspond to any specialized category (e.g., 10-K, IR, ER, IP) and therefore falls into the fallback “Regulatory Filings” category.
2026-05-18 Chinese
天士力第九届董事会第18次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 18th meeting of the 9th Board of Directors of TianShiLi Pharmaceutical Group Co., Ltd. It includes strategic planning, annual board work report, audit committee reports, financial statements approval, profit distribution proposals, and other governance matters. It references the 2025 annual report and other reports but states these are published separately on the Shanghai Stock Exchange website. The document is a formal board meeting resolution announcement, not the full annual report itself. It contains substantive content about board decisions and company strategy, typical of Board/Management Information filings. Therefore, it fits best under the category of Board/Management Information (MANG).
2026-03-19 Chinese
天士力关于对在任独立董事独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a specialized opinion on the independence evaluation of the company's current independent directors, referencing regulatory requirements from the China Securities Regulatory Commission and Shanghai Stock Exchange listing rules. It does not contain financial data, audit results, or management discussion but focuses on governance compliance regarding independent directors. The document length is short (432 characters), and it is a formal statement related to board governance. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2026-03-19 Chinese
天士力2025年年度报告
Annual Report Classification · 100% confidence The document is titled "天士力医药集团股份有限公司2025 年年度报告" which translates to "TASLY Pharmaceutical Group Co., Ltd. 2025 Annual Report." It contains detailed financial data, management discussion and analysis, company overview, financial indicators, audit opinions, and other comprehensive information typical of a full annual report. The document length is substantial (15,000 characters), and it includes signatures from company officers and auditors, detailed financial tables, and extensive narrative sections on business operations, strategy, and risk factors. There is no indication that this is merely an announcement or a summary; rather, it is the full official annual report for the fiscal year 2025. Therefore, the appropriate classification is Annual Report (10-K). FY 2025
2026-03-19 Chinese
天士力2025年度独立董事述职报告（段亚林）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 from a company. It details the independent director's duties, attendance at board and shareholder meetings, communication with auditors, oversight of financial and governance matters, and opinions on company operations and compliance. It is a narrative report on the independent director's activities and assessments during the fiscal year, not a financial report or earnings release. It is not a proxy statement, voting result, or management report. The content aligns with a report on board/management information, specifically focusing on the independent director's role and activities. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 4349 characters, which is sufficient for a detailed report rather than a brief announcement.
2026-03-19 Chinese
天士力2025年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2025 annual profit distribution plan of TianShiLi Pharmaceutical Group Co., Ltd. It details the proposed cash dividend per share, total dividend amount, and related financial figures. The document includes the board's approval and mentions that the plan still requires shareholder meeting approval. It is a formal announcement of a dividend distribution plan rather than the actual dividend payment notice or a full annual report. The document length is 2092 characters, which is relatively short and focused on dividend distribution details. This fits the definition of a Notice of Dividend Amount (DIV) filing, which announces dividend amounts, payment dates, and details for shareholders.
2026-03-19 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.